CSBR (Champions Oncology) EPS (Basic): $-0.16 (TTM As of Jan. 2026)


CSBR Champions Oncology Inc CSBR
64 GF Score
Price $6.14
GF Value $6.62
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Champions Oncology EPS (Basic)?

Champions Oncology CSBR 64 EPS (Basic) is $-0.16 as of Jan. 2026. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review.

Champions Oncology's basic earnings per share (Basic EPS) for the three months ended in Jan. 2026 was $-0.02. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jan. 2026 was $-0.16.

Champions Oncology's EPS (Diluted) for the three months ended in Jan. 2026 was $-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 was $-0.16.

Champions Oncology's EPS without NRI for the three months ended in Jan. 2026 was $-0.02. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jan. 2026 was -0.14.

During the past 12 months, Champions Oncology's average EPS without NRIGrowth Rate was -127.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 105.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Champions Oncology's highest 3-Year average EPS without NRI Growth Rate was 105.30% per year. The lowest was -188.40% per year. And the median was 12.30% per year.

Champions Oncology  (NAS:CSBR) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Champions Oncology EPS (Basic) Related Terms

Champions Oncology EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Champions Oncology's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology EPS (Basic) Chart

Champions Oncology Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.04 -0.39 -0.54 0.34

Champions Oncology Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 -0.13 -0.03 0.02 -0.02
CSBR
64GF Score
Champions Oncology Inc CSBR
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Champions Oncology's Basic EPS for the fiscal year that ended in Apr. 2025 is calculated as

Basic EPS (A: Apr. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(4.701-0)/13.660
=0.34

Champions Oncology's Basic EPS for the quarter that ended in Jan. 2026 is calculated as

Basic EPS (Q: Jan. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.279-0)/13.887
=-0.02

EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.16 mean?
Champions Oncology (CSBR) has a EPS (Basic) of $-0.16 as of Jan. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Champions Oncology and its competitors.
Is Champions Oncology's EPS (Basic) too high?
Champions Oncology's current EPS (Basic) is $-0.16. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's EPS (Basic) compare to ANVS and HYFT?
Champions Oncology's EPS (Basic) of $-0.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Champions Oncology and its competitors. Champions Oncology's current EPS (Basic) is $-0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.14 — trading 7.3% below its estimated fair value. The current EPS (Basic) is $-0.16. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Champions Oncology (CSBR), the current EPS (Basic) is $-0.16 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $6.14 is trading 7.3% below its estimated GF Value™ of $6.62. GuruFocus considers Champions Oncology to be Fairly Valued.

Key valuation signals for CSBR:

  • EPS (Basic): $-0.16
  • GF Value™: $6.62 vs. price of $6.14 (7.3% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score

Get the complete analysis for CSBR

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.14
Price
$6.62
GF Value